re focusing on delivering drugs for rare diseases where the molecular target is found in the liver though their third generation liver centric LNP. TKM-PLK1 is currently in phase II trial and is targeting three different forms of cancer, while TKM-Ebola specialises in the Zaire species of Ebola virus. Th